Disease-free survival and overall survival were similar in a study comparing total abdominal vs total laparoscopy hysterectomy approaches in women with stage I endometrial cancer.
Quality of life was maintained in patients with ovarian cancer who received chemotherapy with concurrent cediranib then cediranib alone as maintenance therapy.
A team of international researchers identified 12 new genetic variants that increase a woman's risk of developing ovarian cancer.
ASCO offers global recommendations for HPV vaccination tailored to structural resource levels of regions.
Self-persuasion is more effective than external persuasion for motivating low-income parents to vaccinate their children against HPV.
A protocol of testing of CA125 levels quarterly with subsequent transvaginal ultrasound examination increased detection of early-stage ovarian cancer in women at high-risk for the disease.
Universal screening of women with gynecologic malignancies for early palliative care decreased the use of aggressive measures at the end of life.
Living in a high-poverty region is associated with lower access to obesity-related self-care resources.
There are 18 core priority symptoms that should be routinely assessed in patients with recurrent ovarian cancer to provide higher quality of care.
Nurse-guided and self-directed web-based symptom management interventions (WRITE Symptoms) improved symptom controllability among women with recurrent ovarian cancer.
Presence of 1 risk factor or 2 or more risk factors is associated with non-home discharge after hysterectomy for gynecologic malignancy.
Study finds that instituting a health system-wide quality metric, such as postoperative hospital readmission rate, may be inconsistent with long-term clinical outcomes goals.
Perioperative Pain Control Reduces Need for Postoperative Narcotics After Hysterectomy for Uterine CancerMarch 15, 2017
Preoperative intravenous acetaminophen plus local infiltration of LB during hysterectomy and surgical staging of uterine cancer may reduce the need for postoperative narcotics.
Perioperative celecoxib use during hysterectomy may reduce the need for oral narcotics after hospital discharge.
Use of chemotherapy or vaginal brachytherapy (VBT) may improve survival among patients with early-stage uterine papillary serous carcinoma.
Nearly 3 in 10 cervical cancer survivors were still using opioids at 6 months after completing radiotherapy.
Nonadherence to NCCN guideline treatment recommendations was strongly associated with decreased survival from early-stage cervical cancer.
The top reasons for not initiating HPV vaccination are necessity, safety, and knowledge, rather than a lack of discussions on sexuality.
A study that integrated genomic and clinical data identified 3 distinct clusters of patients with serous epithelial ovarian cancer who do not respond to chemotherapy.
An enhanced recovery program is more cost-effective than usual care in patients undergoing primary cytoreductive surgery for ovarian cancer.
Rucaparib was active with an acceptable safety profile in patients with relapsed, platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations.
Multidisciplinary team approach reduces cervical cancer treatment delays in Botswana by 50%.
A new generation dual PI3K/mTOR inhibitor shows promise in treating leiomyosarcomas with the protein P-S6S240.
Individuals with serious carcinoma of the ovary or peritoneum experienced improved progression-free survival after hormone maintenance therapy.
The researchers hope the results will lead to an increase in clinicians offering trials to their patients and an increase in women volunteering to participate in trials.
The impact of weight loss on risk for endometrial cancer in postmenopausal women was assessed in women enrolled in the Women's Health Initiative observational study.
The timing of surgery taking place following an endometrial cancer diagnosis may adversely impact survival.
The benefits of primary cytoreductive surgery relative to neoadjuvant chemotherapy remain uncertain; therefore, researchers performed a retrospective data analysis to compare overall survival of surgery with that of neoadjuvant chemotherapy in advanced-stage epithelial ovarian cancer.
Researchers report on the feasibility of a nurse-led sexual rehabilitation intervention to target sexual recovery and vaginal dilation in women who underwent pelvic radiation therapy and brachytherapy for gynecologic cancers.
Smoking-attributable cancer mortality estimates have not been established by state; therefore, in this study, the proportion of cancer deaths among persons 35 years and older related to cigarette smoking in 2014 was calculated for each state and DC.
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Health Care Expansion Tied to Increased Rates of Surgical Treatment of Thyroid Cancer
- Including a PI3-Kinase Inhibitor with an PARP Inhibitor Improves Tumor Shrinkage in Patients with Resistant Ovarian Cancer
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Family History Does Not Exclude Active Surveillance as Treatment Option for Prostate Cancer
- Beans, Whole Grains in Diet Beneficial for Colorectal Cancer Survivors
- Hormone Refractory Prostate Cancer Responds to Abiraterone Acetate in Some Cases
- Shifts in Cancer Burden for People With HIV Projected
- Tissue Biobank Procurement Consent Should Include Discussion of Confidentiality Risks
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|